Heidelberg Pharma also pursues the strategy of site-specific conjugation to limit heterogeneity of drug-antibody species, to improve conjugate stability, and to increase the therapeutic window of ADCs. For this purpose, antibodies are engineered at specific locations to incorporate cysteines resulting in so called THIOMABS.
INTRODUCTION
Triple negative breast cancer (TNBC) is the most difficult to treat subtype of breast cancer with limited therapeutic options. At least 50% of TNBC patients have low human epidermal growth factor receptor 2 (HER2; ERBB2) expression with the majority harboring hemizygous loss of POLR2A/chromosome 17p. For these patients, the treatment with antibody-targeted amanitin conjugates (ATACs) targeting HER2 is a new promising approach. Heidelberg Pharma´s ATACs comprise a new class of antibody-drug conjugates (ADCs) with amanitin as toxic payload (1, 2) . Amanitin, the well-known toxin of the amatoxin family, binds specifically to the eukaryotic RNA polymerase II and thereby efficiently inhibits the cellular transcription process (3, 4) . Antigen low expressing cells can also be targeted with ATACs as inhibition of the transcription is already achieved at very low intracellular concentrations of the toxic payload. Additionally, the gene encoding for the target of amanitin, POLR2A, is close to TP53 on chromosome 17p. The genomic deletion of TP53 frequently leads to passenger deletion of POLR2A and thereby to enhanced sensitivity of the cells towards ATACs.
Cytotoxic potency
The HER2 expressing cancer cell lines SKBR-3, MDA-MB-453, JIMT-1 and T47D as well as HER2 neg. MDA-MB-468 cell line were used to test the cytotoxic potency of HER2-THIOMAB-ATAC with cleavable linker and compared to Kadcyla. While Kadcyla showed only a cytotoxic effect on cell lines with moderate and high HER2 expression, the ATAC showed high cytotoxic activity in a picomolar range on all HER2 high to low expressing cell lines (Figures 2a-d ). 
RESULTS

Mouse efficacy experiments
The antitumor activity of single dose treatment with anti-HER2 ATACs was determined in JIMT-1 xenograft as well as in patientderived xenograft (PDX) subcutaneous (s.c.) models in vivo.
JIMT-1 s.c. xenograft model
Anti-HER2 ATAC with stable linker (Figure 3a ) as well as HER2-THIOMAB-ATAC with cleavable linker (Figure 3b ) showed complete remissions after single dose application of 2.9mg/kg and 2.0mg/kg, respectively. In contrast, Trastuzumab conjugated to DM1 (Kadcyla) did not have any effect (Figure 3a ). 
TNBC HER2low Kadcyla-resistant PDX s.c. models
Anti-HER2-THIOMAB-ATAC with cleavable linker showed dosedependent tumor remission after single dose application of 2.0mg/kg in heterogeneous Kadcyla-resistant HER2low PDX models, which were classified as TNBC ( Figure 4 ). The efficacy of HER2-THIOMAB-ATACs was more pronounced in PDX models with hemizygous loss of TP53 and POLR2A reflecting a 17p deletion. 
Non-human primate tolerability study (off-target tox)
Non-targeting THIOMAB-ATAC was assessed for a dose-escalating tolerability study in cynomolgus monkeys. The ATAC was applied sequentially at doses of 0.3mg/kg, 1.0mg/kg and repeated dosing of 3.0mg/kg to the same animals. Biochemical and hematological blood parameters were evaluated extensively during the study (selected parameters: Figure 5 ).
The Non-targeting THIOMAB-ATAC was well tolerated even with repeated dosing of 3mg/kg dose levels:
-Transient and mild increase in liver-relevant biochemical parameters after application of 3mg/kg. 
HER2-THIOMAB antibody and ATAC bind selectively to HER2 on cancer cell lines
For binding analysis, HER2 + SKBR-3, MDA-MB-453, JIMT-1, T47D as well as HER2 -MDA-MB-468 cell lines were incubated with increasing concentrations of the HER2-THIOMAB antibody or HER2-THIOMAB-ATAC. The antibody as well as ATAC showed the same binding to the cancer cell lines expressing HER2 to different levels (Figures 1a+b) . The generation of the THIOMAB antibody did not influence the binding towards HER2 (data not shown). 
CONCLUSION
Breast cancer is the most commonly occurring cancer in women world-wide. It is classified into several subtypes. HER2 is amplified in a variety of breast cancer patients and even other breast cancer subtypes (e.g. TNBC) express low levels of HER2.
In the current study, the mode of action of the payload amanitin led to an efficient anti-tumor potential in vitro and in vivo. Targeted cytotoxic drug delivery to low, medium and high HER2 expressing cell lines was achieved by using anti-HER2 ATACs. In mouse xenografts anti-HER2 ATACs showed clear anti-tumor activity in Trastuzumab-resistant JIMT-1 model. Heterogeneous Kadcyla-ineffective TNBC PDX models with low levels of HER2 were sensitive to ATAC treatment. Loss of POLR2A/chromosome 17p increased susceptibility to anti-HER2 ATAC making 17p del TNBC a suitable indication for optimized anti-HER2 ATACs. Safety profiling in cynomolgus monkey revealed a good tolerability and low off-target tox for non-targeting ATAC.
In summary, amanitin as a toxic warhead for ADCs targeting HER2low seems to be a suitable therapeutic option because of the unique mode of action and the molecular characteristics of the toxin. Amanitin is also active in drug resistant cells, independent of the expression of multi-drug resistance transporters. This is a potential advantage for amatoxin payloads in slow proliferating or dormant cancer cells. With POLR2A we identified a possible predictive biomarker for ATAC therapies, which might be used to stratify patients. 
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